State of oncology care in Russia: pancreatic cancer (C25). Diagnosis, prevalence, quality of patient registration, and annual mortality. Part 1. (clinical-population study)

Cover Page

Cite item

Full Text

Abstract

The study focuses on pancreatic cancer (C25), a malignant neoplasm arising from the ductal epithelium or glandular tissue of the pancreas, which accounts for 3% of the overall cancer incidence in Russia. The rates of incidence and mortality are rising, with the number of newly registered patients in Russia being lower than the number of recorded deaths, although the one-year mortality rate among patients is decreasing. The direct cause of pancreatic cancer (C25) remains unknown. Risk factors for developing this condition include genetics, smoking, alcohol abuse, a sedentary lifestyle, excessive meat consumption, and a lack of plant-based foods in the diet. Diseases associated with a high risk of this pathology include long-standing chronic pancreatitis, newly diagnosed type 2 diabetes in individuals aged 50-70, and cystic neoplasms of the pancreas. The aim of the study is to examine the patterns of incidence and mortality, the quality of patient registration, the characteristics of tumor localization, and the histological structure of pancreatic cancer (C25). The study will also track the nature of annual mortality among patients and explore the possibilities, methods, and techniques of modern diagnosis and treatment for these patients. The research confirmed the significant burden of pancreatic cancer (C25), primarily due to the late detection of this disease. The study provided sufficient material to analyze age-related risk factors, as well as the patterns of incidence and mortality in the population. It also examined and presented mortality rates among patients, including during the first year of observation.

About the authors

Vakhtang M. Merabishvili

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation

Author for correspondence.
Email: MVM@niioncologii.ru
ORCID iD: 0000-0002-1521-455X
SPIN-code: 5705-6327

Honored Scientist of the Russian Federation, Dr.Med.Sci., Professor, Head of the Department of Cancer Statistics

Russian Federation, Saint Petersburg

Sergey S. Bagnenko

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation; Saint Petersburg State Pediatric Medical University

Email: bagnenko_ss@mail.ru
ORCID iD: 0000-0002-4131-6293
SPIN-code: 4389-9374
Scopus Author ID: 779096

DSc Med., Professor, Head of Scientific Department, Leading researcher of the N. N. Petrov National Medicine Research Center of Oncology Ministry of health of Russia, Professor of the Department of Radiation Diagnostics and Biomedical Imaging of the Federal State Budgetary Educational Institution of Higher Education St. Petersburg State Pediatric Medical University of the Ministry of Health of Russia

Russian Federation, Saint Petersburg; Saint Petersburg

Pavel V. Balakhnin

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation

Email: balahnin_p@mail.ru

PhD in Medical Sciences, Senior Researcher of the Scientific Department of Diagnostic and Interventional Radiology, Head of the Department of X-ray Surgical Methods of Diagnostics and Treatment

Russian Federation, Saint Petersburg

Ekaterina A. Busko

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation; Saint Petersburg State University

Email: Katrn@mail.ru

DSc Med., Assoc. Prof., Leading researcher of the N. N. Petrov National Medicine Research Center of Oncology Ministry of health of Russia; Professor of Saint Petersburg State University

Russian Federation, Saint Petersburg; Saint Petersburg

Alexander V. Pavlovsky

Russian Research Center for Radiology and Surgical Technologies

Email: surgepon@gmail.com

DSc Med., Chief Researcher

Russian Federation, Saint Petersburg

Vladislav E. Moiseenko

Russian Research Center for Radiology and Surgical Technologies; Pavlov First Saint Petersburg State Medical University (Pavlov University)

Email: tmpr@inbox.ru

Candidate of Medical Sciences, Oncologist at the Russian Scientific Center of Radiology and Surgical Technologies named after Academician A. M. Granov of the Ministry of Health of the Russian Federation; Associate Professor of the Department of Radiology and Surgical Technologies of the First St. Petersburg State Medical University named after Academician I. P. Pavlov of the Ministry of Health of the Russian Federation

Russian Federation, Saint Petersburg; Saint Petersburg

Vladimir V. Perelygin

Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation

Email: vladimir.pereligin@pharminnotech.com
ORCID iD: 0000-0002-0999-5644
SPIN-code: 3128-7451
Scopus Author ID: 13105602000
ResearcherId: AAV-6556-2020

Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Industrial Ecology Department

Russian Federation, Saint Petersburg

References

  1. Malignant neoplasms in Russia in 2022 (morbidity and mortality) / Kaprin A. D., Starinsky V. V., Shakhzadova A. O., Lisichnikova I. V. // Moscow: P. A. Hertsen MNIOI. – 2023. – 275 p. (In Russ).
  2. Shangina O. V. Descriptive, analytical and molecular epidemiology of pancreatic cancer / O. V. Shangina, D. M. Maksimovich, D. G. Zaridze // Siberian journal of oncology. – 2022. – Vol. 21, No. 3. – P. 90–103. – doi: 10.21294/1814-4861-2022-21-3-90-103. (In Russ).
  3. National Cancer Institute SEER Stat Fact Sheets: Pancreas Cancer [Internet] [cited 2007 Feb 21]. URL: https://seer.cancer.gov/statfacts/html/pancreas.html
  4. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019; 4(12):934–947. doi: 10.1016/S2468-1253(19)30347-4.
  5. Capasso M., Franceschi M., Rodriguez-Castro K.I., Crafa P., Cambiè G., Miraglia C., Barchi A., Nouvenne A., Leandro G., Meschi T., De’ Angelis G.L., Di Mario F. Epidemiology and risk factors of pancreatic cancer. Acta Biomed. 2018; 89(9):141–146. doi: 10.23750/abm. v89i9-S.7923
  6. Prokhorov A. V. Opukholi podzheludochnoi zhelezy: ucheb.-metod. posobie / A.V. Prokhorov, M.N. Shepet’ko, V.E. Papok; Belorus. gos. med. un-t, Kaf. onkologii. – Minsk: BGMU, 2013. – 32 p. (In Russ).
  7. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. doi: 10.3322/caac.21590.
  8. Cancer Incidence in Five Continents. Volume XII. Registry Summary tables. https://ci5.iarc.fr/ci5-xii/tables/summary
  9. Malignant neoplasms in Russia in 2015 (morbidity and mortality) / Kaprin A. D., Sprinsky V. V., Petrova G. V. // Moscow: P. A. Hertsen MNIOI. – 2017. – 250 p. (In Russ).
  10. Malignant neoplasms in Russia in 2010 (morbidity and mortality) / Chissov V. I., Starinsky V. V., Petrova G. V. // Moscow: P.A. Hertsen MNIOI. – 2012. – 260 p. (In Russ).
  11. Malignant neoplasms in Russia in 2019 (morbidity and mortality) / Kaprin A. D., Starinsky V. V., Shakhzadova A. O. // Moscow: P. A. Hertsen MNIOI. – 2020. – 214 p. (In Russ).
  12. Malignant neoplasms in Russia in 2020 (morbidity and mortality) / Kaprin A. D., Starinsky V. V, Shakhzadova A. O. // Moscow: P. A. Hertsen MNIOI. – 2021. – 252 p. (In Russ).
  13. Malignant neoplasms in Russia in 2021 (morbidity and mortality) / Kaprin A. D., Starinsky V. V., A. O. Shakhzadova // Moscow: P. A. Hertsen MNIOI. – 2022. – 252 p. (In Russ).
  14. Malignant neoplasms in Russia in 2000 (morbidity and mortality) / Chissov V.I., Starinsky V.V. // Moscow: P. A. Hertsen MNIOI. 2002:264. (In Russ).
  15. Merabishvili V. M. Analytical indicators. accounting reliability index / V. M. Merabishvili // Issues of oncology. – 2018. – Vol. 64, No. 3. – P. 445–452. (In Russ).
  16. Merabishvili V. M. The index of reliability of accounting is the most important criterion for an objective assessment of the activities of the oncology service for all localizations of malignant neoplasms, regardless of the mortality rate of patients / V. M. Merabishvili // Issues of oncology. – 2019. – Vol. 65, No. 4. – P. 510–515. (In Russ).
  17. Merabishvili V. M. Analytical indicators. Annual mortality of patients with malignant neoplasms in each year of observation / V. M. Merabishvili // Issues of Oncology. – 2021. – Vol. 67, No. 1. – P. 44–50. – doi: 10.37469/0507-3758-2021-67-1-44-50. (In Russ).
  18. Merabishvili V. M. Mediko-statisticheskii terminologicheskii slovar’: metodicheskoe posobie dlya vrachei, ordinatorov, aspirantov i nauchnykh sotrudnikov. Izdanie vtoroe, dopolnennoe terminami, illyustratsiyami i avtorskimi kommentariyami. – M., Vol. 8. Izdatel’skie tekhnologii, 2021. – 120 p. (In Russ).
  19. Yamashita Y., Shimokawa T., Ashida R., Dietrich C. F., D’Onofrio M., Hirooka Y., Kudo M., Mori H., Sofuni A., Kitano M. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. ltrasound Med Biol. 2021;47(12): 3315–3322. doi: 10.1016/j.ultrasmedbio.2021.08.005.
  20. Mikhetko A. A. Endoscopic endosonography with fine-needle aspiration biopsy in the diagnosis of pancreatic tumors / A. A. Mikhetko, A. S. Artemyeva, O. V. Ivko [et al.] // Issues of oncology. – 2021. – Vol. 67, No. 3. – P. 397–404. – doi: 10.37469/0507-3758-2021-67-3-397-404. (In Russ).
  21. Shin C. M., Villa E. The efficiency of contrast-enhanced endoscopic ultrasound (EUS) combined with EUS elastography for pancreatic cancer diagnosis: a systematic review and meta-analysis. Ultrasonography. 2023;42(1): 20–30. doi: 10.14366/usg.22103.
  22. Hassan G. M., Laporte L., Paquin S. C., Menard C., Sahai A. V., Mâsse B., Trottier H. Endoscopic Ultrasound Guided Fine Needle Aspiration versus Endoscopic Ultrasound Guided Fine Needle Biopsy for Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2022; 12(12):2951. doi: 10.3390/diagnostics12122951.
  23. Paramythiotis D., Karlafti E., Tsavdaris D., Arvanitakis K., Protopapas A. A., Germanidis G., Kougias L., Hatzidakis A., Savopoulos C., Michalopoulos A. Comparative Assessment of Endoscopic Ultrasound-Guided Biopsies vs. Percutaneous Biopsies of Pancreatic Lesions: A Systematic Review and Meta-Analysis of Diagnostic Performance. J Clin Med. 2024;13(11):3108. doi: 10.3390/jcm13113108.
  24. Kudryavtseva A. V. CT and MRI in the assessment of resectable and conditionally resectable pancreatic tumors / A. V. Kudryavtseva, S. S. Bagnenko, I. I. Dzidzava [et al.] // Annals of Surgical Hepatology. – 2021. – Vol. 26, No. 1. – P. 34–47. – doi: 10.16931/1995-5464.2021134-47. (In Russ).
  25. Nesterov D. V. Dynamic computed tomography in patients with pancreatic cancer. Evaluation of perfusion in the tumor and in the parenchyma of the gland outside it / D. V. Nesterov, E. V. Rosenhaus // Medical visualization. – 2014. – No. 2. – P. 68–74. (In Russ).
  26. Badgery H. E., Muhlen-Schulte T., Zalcberg J. R., D’souza B., Gerstenmaier J. F., Pickett C., Samra J., Croagh D., Pancreatic Cancer Image Biobank Authorship Group. Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey. HPB (Oxford). 2023; 25(11):1393–1401. doi: 10.1016/j.hpb.2023.07.883.
  27. Yan X., Lv K., Xiao M., Tan L., Gui Y., Zhang J., Chen X., Jia W., Li J. The diagnostic performance of contrast-enhanced ultrasound versus contrast-enhanced computed tomography for pancreatic carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2022;11(10): 3645–3656. doi: 10.21037/tcr-22-601.
  28. Rahman M. I. O., Chan B. P. H., Far P. M., Mbuagbaw L., Thabane L., Yaghoobi M. Endoscopic ultrasound versus computed tomography in determining the resectability of pancreatic cancer: A diagnostic test accuracy meta-analysis. 2020;26(3):113–119. doi: 10.4103/sjg.SJG_39_20.
  29. Alabousi M., McInnes M. D., Salameh J-P., Satkunasingham J., Kagoma Y. K., Ruo L., Meyers B. M., Aziz T., Pol C. B. MRI vs. CT for the Detection of Liver Metastases in Patients With Pancreatic Carcinoma: A Comparative Diagnostic Test Accuracy Systematic Review and Meta-Analysis. J Magn Reson Imaging. 2021;53(1):38–48. doi: 10.1002/jmri.27056.
  30. Ikuta Y., Takamori H., Ikeda O., Tanaka H., Sakamoto Y., Hashimoto D., Ozaki N., Nakahara O., Furuhashi S., Abe S., Beppu T., Shimada S., Yamashita Y., Baba H. Detection of liver metastases secondary to pancreatic cancer: utility of combined helical computed tomography during arterial portography with biphasic computed tomography-assisted hepatic arteriography. J Gastroenterol. 2010;45(12): 1241–1246. doi: 10.1007/s00535-010-0285-6.
  31. Balakhnin P. V. The nature and perfusion dynamics of peritumoral ring contrast enhancement of small (5–9 mm) and very small (<5 mm) hypovascular liver metastases: Analysis of dynamic CT arteriohepaticography data / P. V. Balakhnin, A. S. Shmelev, E. G. Shachinov [et al.] // Practical oncology. – 2017. – Vol. 18, No. S1. – P. 58–78. (In Russ).
  32. Trufanov G. E. Radiation diagnostics of pancreatic diseases: normal radiation anatomy of the pancreas, description of radiation semiotics of diseases and injuries of the pancreas, tactics of radiation examination, issues of etiology, pathogenesis, morphology and clinical manifestations of diseases / G. E. Trufanov, S. D. Rud, S. S. Bagnenko; G. E. Trufanov, S. D. Rud, S. S. Bagnenko. – 2nd ed., corrected. – St. Petersburg: ELBI-SPb, 2011. – 287 p. – (Briefs of a radiation diagnostician). – ISBN 978-5-93979-235-6. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Malignant neoplasms in some countries of the world. Pancreas. C25. Men. 2013-2017. IARC “Cancer on 5 continents”. Volume XII. Cancer incidence in Five Continents. Males. V. XIII ARC. 2013–2017 [1, 8, 9]

Download (155KB)
Indexing metadata
3. Fig. 2. Malignant neoplasms in some countries of the world. Pancreas. C25. Women. 2013–2017. IARC “Cancer on 5 continents”. Volume XII. The incidence of cancer on five continents. Women. V. XII IARC. 2013–2017 [1, 8, 9]

Download (149KB)
Indexing metadata
4. Fig. 3. Age-related incidence of pancreatic cancer among the male population in some countries of the world. IARC “Cancer on five Continents”, Volume 12 [1, 8, 9]

Download (120KB)
Indexing metadata
5. Fig. 4. Age-related indicators of the incidence of pancreatic cancer in the female population in some countries of the world. IARC “Cancer on five Continents”, Volume 12 [1, 8, 9]

Download (122KB)
Indexing metadata
6. Fig. 5. Incidence of pancreatic cancer in Russia (standardized indicators) [1, 10–13]

Download (91KB)
Indexing metadata
7. Fig. 6 from the table. Age-related dynamics of pancreatic cancer incidence (C25) in the Russian population by age group, 2000 and 2022. Both sexes [1, 14]

Download (148KB)
Indexing metadata
8. Fig. 7 from the table. Age-related dynamics of pancreatic cancer incidence (C25) in the Russian population by age group, 2000 and 2022. Men [1, 14]

Download (139KB)
Indexing metadata
9. Fig. 8 from the table. Age-related dynamics of pancreatic cancer incidence (C25) in the Russian population by age group, 2000 and 2022. Women [1, 14]

Download (129KB)
Indexing metadata
10. Fig. 9. Mortality of the Russian population from pancreatic cancer (C25) (standardized indicators) [1, 10–13]

Download (72KB)
Indexing metadata
11. Fig. 10 from the table. Dynamics of the index of reliability of accounting for pancreatic cancer (C25) in Russia and the Northwestern Federal District of the Russian Federation [1, 9–13]

Download (146KB)
Indexing metadata
12. Fig. 11 from the table. Typical mortality of patients with pancreatic cancer (C25) in the Northwestern Federal District of the Russian Federation. Database of the population cancer registry of the Northwestern Federal District of the Russian Federation. Both sexes

Download (268KB)
Indexing metadata

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».